ACTIVAERO RECEIVES RESEARCH GRANT FOR DEVELOPMENT OF THERAPY AGAINST CHRONIC LUNG DISEASES
(Thomson Reuters ONE) -
Activaero GmbH /
ACTIVAERO RECEIVES RESEARCH GRANT FOR DEVELOPMENT OF THERAPY AGAINST CHRONIC
LUNG DISEASES
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Munich m4 biotech cluster program extends support for the development of a
novel method to treat chronic lung diseases
* Program focuses on targeted treatment of the lung with biotherapeutics
Gemuenden/Wohra, Germany, June 18, 2013 - Activaero GmbH, the therapeutic area
specialist for respiratory diseases focusing on novel, pharmacoeconomically
meaningful treatment solutions, today announced that the Company is to receive
additional financial support for the development of a novel treatment for
chronic non-infectious lung diseases. As part of the Munich-based biotech
cluster program m4, the grant is going to support research performed at
Activaero and the Comprehensive Pneumology Center (CPC) in Munich.
The new extended collaboration now aims specifically at advancing the
preclinical development of techniques to deposit aerosolized biotherapeutics via
inhalation directly into specific lung regions and to therewith more effectively
treat non-infectious lung diseases. Originally, the joint research project
started in 2010 and was geared towards identifying a novel inhalation method
allowing for efficacy testing of new inhaled substances in preclinical research.
Following this first stage of work, aerosol experts at Activaero and CPC are now
going to investigate the effectiveness of certain biotherapeutics in a cell-
based system before the drugs will then be evaluated in selected preclinical
models. This work will help identifying new biotherapeutics for the treatment of
chronic lung diseases and to better understand their safety and efficacy.
"According to the WHO, lung diseases are the second most common cause of death
worldwide. Therefore, a particular high need exists for new highly effective
therapies in the field of chronic non-infectious lung diseases. It is our goal
to develop therapies that affect the cause of the disease, significantly relieve
the symptoms and, potentially, cure the disease. Complex high molecular weight
biological substances, so called biotherapeutics appear to be very promising as
their mechanism of action might address severe respiratory diseases at their
root cause." explained Bernhard Müllinger, Chief Technical Officer of Activaero.
About the leading-edge cluster program 'm4 - Personalized Medicine and Targeted
Therapies'
The research collaboration between Activaero and the Munich-based Comprehensive
Pneumology Center is funded by the initiative 'm4 - Personalised Medicine and
Targeted Therapies' for which the Munich Biotech Cluster was awarded 'Leading-
edge cluster status' by the German Federal Ministry of Research and Education
(BMBF) in 2010. For a 5 year period, the program is funded with EUR 40 million
from the BMBF, which are complemented by EUR 40 million from the participating
companies in more than 40 cooperative R&D projects from industry and scientific
institutions. The Bavarian Ministry of Economic Affairs, Infrastructure,
Transport and Technology supports the cluster management agency BioM and
particular components of the concept with an additional EUR 12 million.
For further information please visit:
http://www.m4.de/personalisierte-medizin/spitzencluster-muenchen/der-
wettbewerb.html
About The Comprehensive Pneumology Center (CPC)
The CPC was jointly founded by Helmholtz Zentrum München (German Research Center
for Environmental Health), Ludwig Maximilians University Munich, University
Clinics Munich and Asklepios Pulmonary Hospital in Munich-Gauting. The research
in the CPC is focused on chronic lung diseases. CPC scientists integrate methods
of molecular and cell biology, pharmacology, molecular pathology and clinical
medicine in order to develop new diagnostic tools and therapies for chronic lung
diseases.
About Activaero
Activaero is a therapeutic area specialist developing new, pharmacoeconomically
meaningful treatment solutions for patients suffering from severe respiratory
diseases, including Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic
Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension.
Activaero was founded in 1998 in Germany and is a privately held company with
offices in Germany near Frankfurt and Munich as well as in Dublin, Ohio (USA).
www.activaero.de
Contact us:
Activaero GmbH Media Contact
Dr. Gerhard Scheuch Anne Hennecke
Chief Executive Officer MC Services AG
t: +49-6453-64818-16 t: +49-89-210228-18
e: info(at)activaero.de e: anne.hennecke(at)mc-services.eu
www.activaero.com
Press release (PDF):
http://hugin.info/156033/R/1710024/566857.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Activaero GmbH via Thomson Reuters ONE
[HUG#1710024]
Unternehmensinformation / Kurzprofil:
Datum: 18.06.2013 - 09:00 Uhr
Sprache: Deutsch
News-ID 270591
Anzahl Zeichen: 5921
contact information:
Town:
Gemuenden/Wohra
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 136 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ACTIVAERO RECEIVES RESEARCH GRANT FOR DEVELOPMENT OF THERAPY AGAINST CHRONIC LUNG DISEASES"
steht unter der journalistisch-redaktionellen Verantwortung von
Activaero GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
